Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lee Cohen

Psychiatry Hastings On Hudson, NY Medical Doctor

NPI 1174669683 CMS profile 280469

623 Warburton Ave, Hastings On Hudson, NY 10706

Open in the dashboard

General payments

$690,173

1,082 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$329,332 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Lee Cohen of Hastings On Hudson, NY is reported in the CMS Open Payments database as having received $690,173 across 1,082 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $329,332 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $212,594 292
2024 General $132,944 190
2023 General $64,943 113
2022 General $43,217 41
2021 General $64,542 60
2020 General $77,110 109
2019 General $94,823 277

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Cohen
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Lee Cohen were reported at $212,594. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Lee Cohen Psychiatry median Middle half National median
2019 $94,823 $184 $59–$605 $163
2020 $77,110 $119 $36–$372 $114
2021 $64,542 $143 $43–$576 $132
2022 $43,217 $153 $50–$590 $149
2023 $64,943 $170 $56–$651 $160
2024 $132,944 $179 $57–$673 $164
2025 $212,594 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $279,965 408 payments
  2. E.R. Squibb & Sons, L.L.C. $129,537 156 payments
  3. Allergan Inc. $92,397 184 payments
  4. Ironshore Pharmaceuticals Inc. $54,440 108 payments
  5. Axsome Therapeutics, Inc. $46,247 48 payments
  6. Corium, Inc. $34,146 47 payments
  7. Sunovion Pharmaceuticals Inc. $24,920 54 payments
  8. Tris Pharma Inc $9,190 15 payments
  9. Neurocrine Biosciences, Inc. $8,230 17 payments
  10. Supernus Pharmaceuticals, Inc. $6,152 10 payments
  11. Other $4,949 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $546,336 255 payments
  2. Consulting Fee $46,866 21 payments
  3. Honoraria $44,726 24 payments
  4. Travel and Lodging $25,522 361 payments
  5. Food and Beverage $21,615 418 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $5,000 1 payment
  7. Education $108 2 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $192,600 274 payments
  2. VRAYLAR Neuroscience $179,130 315 payments
  3. COBENFY Neuroscience $65,588 96 payments
  4. Auvelity $46,187 47 payments
  5. Azstarys $34,146 47 payments
  6. Jornay PM 20mg capsules (Bottle of 100) $28,447 76 payments
  7. JORNAY PM $25,993 32 payments
  8. LATUDA $24,100 53 payments
  9. COBENFY Psychiatry/Psychology $16,600 22 payments
  10. Dyanavel XR $9,139 12 payments
  11. Other $32,087 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

200

Median for Psychiatry & Neurology: 100

Drug cost

$8,526

Median for Psychiatry & Neurology: $2,986

Branded share of claims

32%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Risperdal Risperidone Brand 11 $4,155
Fluvoxamine Maleate Generic 17 $1,103
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 24 $922
Vilazodone Hcl Generic 12 $736
Divalproex Sodium Er Divalproex Sodium Brand 17 $620
Lorazepam Generic 41 $313
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 12 $260
Escitalopram Oxalate Generic 32 $173
Buspirone Hcl Generic 20 $166
Clonazepam Generic 14 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$72,414 — —
COBENFY
$16,600 — —
Auvelity
$8,237 — —
Azstarys
$1,020 — —
Sunosi
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,082 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record